Poster Abstract Session:
148. C. difficile: From the Bench to Bedside
Friday, October 6, 2017: 12:30 PM-2:00 PM
Room: Poster Hall CD


Presentations:
Engraftment and Augmentation of Microbiome Following Fecal Microbiota Transplantation for Recurrent Clostridium difficile infection
Christine Lee, MD, FRCPC; Stephen Rush, PhD; J. Scott Weese, DVM; Peyman Goldeh, B.Eng; Peter Kim, PhD
Posters
  • Poster.pdf (730.8 kB)
  • Lyophilized fecal microbiota transplantation capsules for recurrent Clostridium difficile infection
    Hebert Dupont, MD; Zhi-Dong Jiang, MD, DrPH; Ashley Alexander, MHSA; Nadim Ajami, PhD; Joseph F. Petrosino, Ph.D.; Andrew W. DuPont, MD, MS; Shi Ke, MD; Goo Jun, PhD; Craig Hanis, PhD
    Socioeconomic Status Factors Associated with Increased Incidence of Community-Associated Clostridium difficile Infection
    Kimberly Skrobarcek, MD; Yi Mu, PhD; Lisa G. Winston, MD; Geoff Brousseau, MPH; Carol Lyons, MS, MPH; Monica Farley, MD, FIDSA; Rebecca Perlmutter, MPH; Stacy Holzbauer, DVM, MPH; Erin C. Phipps, DVM, MPH; Ghinwa Dumyati, MD, FSHEA; Zintars G. Beldavs, MS; Marion Kainer, MBBS, MPH, FSHEA; Alice Guh, MD, MPH
    Prevalence of Clostridium difficile and Multidrug Resistant Gram-negative rods in the Soil from Southeastern Wisconsin
    Angela Lor, NA; Cathy Tran, N/A; Annette Jencson, BSMT(ASCP)SM, CIC; Jennifer Cadnum, B.S.; Curtis J. Donskey, MD; L. Silvia Munoz-Price, MD, PhD
    Change in bacterial diversity of fecal microbiota drives mortality in a hamster model of antibiotic-induced Clostridium difficile colitis
    Charles Burdet, M.D., MPH; Thu Thuy Nguyen, PhD; Nathalie Saint-Lu, PhD; Sakina Sayah-Jeanne, PhD; Perrine Hugon, PharmD, PhD; Frédérique Sablier-Gallis, PharmD, PhD; Stéphanie Ferreira, PhD; Antoine Andremont, MD, PhD; France Mentré, MD, PhD; Jean De Gunzburg, PhD
    Posters
  • 2017.09.12_posterIDWeek.pdf (1.1 MB)
  • CD4+ T Cells Specific for C. difficile Toxins are a Marker of Patients with Active Relapsing Disease
    Laura Cook, PhD; May Wong, BSc; William Rees, MSc; Torey Lau, BSc; Megan Levings, PhD; Theodore Steiner, MD
    Discordance of SHEA/IDSA Clostridium difficile Disease Severity Scale in Solid Organ Transplant Patients
    Tiffany Lee, PharmD; Christopher McCoy, PharmD, BCPS-AQ ID; Carolyn D. Alonso, M.D.; Graham M. Snyder, MD, SM; Christin Rogers, PharmD, BCPS, FFCP; Katelyn Richards, PharmD, BCPS; Elizabeth B. Hirsch, PharmD, BCPS; Monica V. Mahoney, PharmD, BCPS-AQ ID
    Prospective, open-label trial to evaluate efficacy of lyophilized fecal microbiota transplantation for treatment of recurrent C. difficile infection 
    Peyman Goldeh, B.Eng; Peter Kim, PhD; Salaheddin Abouanaser, MD, FRCPC; Eric Partlow, MD, FRCPC; Patricia Beckett, RN; Catherine Onishi, MLT; Marek Smieja, MD, PhD; Christine Lee, MD, FRCPC
    Efficacy of oral vancomycin, oral metronidazole, or IV metronidazole prophylaxis at reducing the risk of Clostridium difficile recurrence.
    Matthew O'Connell, Pharm.D. Candidate 2018; Judianne Slish, Pharm. D., BCPS; Mark Shelly, MD, FSHEA
    Tetracyclines are Associated with a Reduced Risk of Clostridium difficile Infection: A Systematic Review and Meta-analysis
    Raseen Tariq, MBBS; Janice Cho, MD; Saloni Kapoor, MBBS; Robert Orenstein, DO, FIDSA; Siddharth Singh, MBBS, MS; Darrell Pardi, MD, MS; Sahil Khanna, MBBS, MS
    Durability and Long-Term Clinical Outcomes of Fecal Microbiota Transplant (FMT) Treatment in Patients with Recurrent C. difficile Infection
    Yafet Mamo, BS; Michael Woodworth, MD, MSc; Kaitlin Sitchenko, BS; Tanvi Dhere, MD; Colleen Kraft, MD, MSc
    Fecal microbiota transplantation (FMT) for recurrent/refractory Clostridium difficile infection (CDI) in pediatric immunocompromised patients: a single center experience
    Natasha Kwendakwema, BA; M. Kyle Jensen, MD; Andrew Pavia, MD, FIDSA, FSHEA, FPIDS; Elizabeth Doby Knackstedt, MD, FAAP
    Weight Changes in Fecal Microbiota Transplant for Clostridium difficile
    Dina Hussam, MD; Marci Drees, MD, MS; Scott Myerson, MD; Chad Duffalo, MD, MPH; Danielle Mosby, MPH; Christine Herdman, MD; Fedele Depalma, MD; Patty Mcgraw, RN, MS; Alfred E. Bacon Iii, MD
    Comparison of Fidaxomicin and Vancomycin for Recurrent Clostridium difficile Colitis
    Teresa Khoo, MD; Zachary Fleischner, MD; Robert Chow, MD; Melinda Monteforte, PharmD; Luis A. Marcos, MD, MPH
    Posters
  • Cdiff poster 2017.pdf (282.7 kB)
  • Factors Affecting Effectiveness of Fecal Microbiota Transplant
    Danielle Mosby, MPH; Patty Mcgraw, RN, MS; Chad Duffalo, MD, MPH; Marci Drees, MD, MS; Fedele Depalma, MD; Christine Herdman, MD; Scott Myerson, MD; Alfred E. Bacon Iii, MD
    Cost Effectiveness Analysis of Fecal Transplant Delivery Methods for Recurrent Clostridium difficile Infections in Outpatients
    Jeremey Walker, M.D.; Nathan Gundacker, MD; Martin Rodriguez, MD, FIDSA; Ellen Eaton, MD
    Posters
  • CEA CDI Poster 10.1.pdf (1.7 MB)
  • Ribotypes matter, significance of Clostridium difficile ribotypes in cancer patients with diarrhea.
    Eduardo Yepez Guevara, MD; Harika Yalamanchili, MD; Andrew Chao, MD; Kevin Garey, PharmD, MS; Micah Bhatti, MD, PhD; Samuel L. Aitken, PharmD; Pablo C. Okhuysen, MD, FACP, FIDSA
    Bezlotoxumab (BEZ) for Prevention of Clostridium Difficile Infection (CDI) Recurrence (rCDI): Outcomes in Patients with Substantial Renal Impairment (SRI)
    Yoav Golan, MD; Herbert L. DuPont, MD; Fernando Aldomiro, MD; Erin H. Jensen, MS; Mary E. Hanson, PhD; Mary Beth Dorr, PhD
    Changes to the Composition of the Gastrointestinal Microbiome after Probiotics for Clostridium difficile Infection in Adults
    Shoshannah Eggers, BS; Travis De Wolfe, MS; Anna Barker, Ba; Megan Duster, MT(ASCP); Kimberly Dill-McFarland, PhD; Garret Suen, PhD; Nasia Safdar, MD, PhD
    Endogenous Serum IgG Antibodies to Clostridium difficile Toxin B Are Associated with Protection against C. difficile Infection Recurrence
    Ciaran P. Kelly, MD; Ian R. Poxton, PhD, DSc; Judong Shen, PhD; Radha Railkar, PhD; Dalya Guris, MD; Mary Beth Dorr, PhD
    Comparative Effectiveness of Vancomycin Versus Metronidazole in Mild Clostridium difficile Infections, and Potential Impact on Subsequent Vancomycin-Resistant Enterococcus (VRE) Isolation.
    Ilan Youngster, MD, MMSc; Zipora Lazarovitch, Phd; Marina Bondorenco, MD; Betlehem Mengesha, MD; Limor Toledano, MD; Yael Kachlon, MD; Dror Marchaim, MD
    Gastrointestinal Tract Microbiome Dynamics Following Treatment with SER-109, an Investigational Oral Microbiome Therapeutic to Reduce the Recurrence of Clostridium Difficile Infection (CDI)
    Matthew Henn, Ph.D.; Christopher Ford, Ph.D.; Edward O'Brien, Ph.D.; Jennifer Wortman, Ph.D.; Sheri Simmons, Ph.D.; Liyang Diao, Ph.D.; Kevin Litcofsky, Ph.D.; Patricia Bernardo, Sc.D.; John Aunins, Ph.D.; David Cook, Ph.D.; Michele Trucksis, Ph.D., M.D.
    Initial Oral Vancomycin Versus Oral Vancomycin After Metronidazole for Severe Clostridium difficile Infection
    Sunish Shah, PharmD; Benjamin Ereshefsky, PharmD, BCPS; Laura Pontiggia, PhD; Michael Cawley, PharmD, RRT, CPFT, FCCM
    Posters
  • IDWeek poster 9.24.17.pdf (412.6 kB)
  • CME Credits: Maximum of 0.00 hours of AMA PRA Category 1 Credit™


    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 4th with the exception of research findings presented at the IDWeek press conferences.